Blood Cancer Treatment: Ciltacabtagene Autoleucel

We are studying the effects of a new infusion treatment for patients with blood cancers. The trial compares different ways of administering the treatment to see which is more effective and safe.

What diseases are being studied?

Health conditions and diseases that the clinical trial is designed to study and treat.

Who can participate in the clinical trial?

These questions help us understand your situation so we can let the trial team know whether you might be a potential match. This is not a medical evaluation and is not part of the official screening, the study doctor will make the final decision..

What medicines are being studied?

Medicines that are officially approved for use in the European Union and considered safe by EMA. These medicines are already on the market and may be tested for new conditions or populations.

Carvykti
Carvykti is a personalized cell therapy used to treat adults with relapsed or hard-to-treat multiple myeloma.

What active substances are being studied?

Active substances that are officially approved for use in the European Union and considered safe by EMA. These substances are already on the market and may be tested for new conditions or populations.

Ciltacabtagene Autoleucel
Ciltacabtagene autoleucel is a personalized cell therapy using a patient’s own modified immune cells to target and treat advanced multiple myeloma.

What experimental substances are being tested?

Experimental substances that are being investigated in this clinical trial. These are not yet approved for general use.

Jnj-68284528

Where is the clinical trial being conducted?

Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.

Loading map...
Hospital Germans Trias I Pujol
Hematologia
Badalona, Spain
Clinica Universidad De Navarra
Hematologia
Barañáin, Spain
Hospital Universitari Vall D Hebron
Hematologia
Barcelona, Spain

Sponsor: Janssen Cilag International
Last updated: Nov 27, 2025

Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.